sutures newsletter


Mark Your Calendar

Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.

Grand Rounds

Click here to view a schedule of all upcoming grand rounds.

Educational Schedule

Click the PDF link below to see the Department of Surgery's educational schedule for March.

Educational Schedule - March 2014 (PDF)

Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

FDA Reviews Saxagliptin Risk; Victrelis Label Changed

Pharmacy Focus

The U.S. Food and Drug Administration has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the Type 2 diabetes drug and heart failure. In addition, the FDA said the label of the hepatitis C drug Victrelis (boceprevir) has been updated to include information about serious reported cases of pancytopenia.

The FDA's request regarding saxagliptin resulted from a study published in the New England Journal of Medicine, which reported an increased rate of hospitalization for heart failure with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.

The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to FDA by early March.

At this time, the FDA considers information from the study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of all Type 2 diabetes drug therapies and cardiovascular risk.

The FDA says patients should not stop taking saxagliptin.

To learn more, visit this FDA Web page.

Risk of Pancytopenia Added to Victrelis Label

The FDA said the label of the hepatitis C drug Victrelis has been updated to include information about serious cases of pancytopenia that have been reported in patients receiving Victrelis in combination with peginterferon alfa and ribavirin. Complete blood counts (with white blood cell differential counts) should be obtained at pretreatment and at treatment weeks two, four, eight and 12, the FDA said. Blood counts should be monitored closely at other times, as clinically appropriate.

The label also was updated to include the risk of agranulocytosis, thrombocytopenia, pneumonia and sepsis.

The complete revised label can be viewed here.